Evidence map›Paper›PMID 36157994›Full record

ArticleWorld journal of clinical cases2022

Transcatheter arterial infusion chemotherapy and embolization for primary lacrimal sac squamous cell carcinoma: A case report.

Ming-Hui Sun, Wei-Dong Yi, Ling Shen, Lu Zhou, Jian-Xun Lu

Abstract readCase Reports
In one paragraph

Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ming-Hui SunDepartment of Oncology, The First People's Hospital of Nanning, Nanning 530022, Guangxi Zhuang Autonomous Region, China.
Wei-Dong YiDepartment of Oncology, The First People's Hospital of Nanning, Nanning 530022, Guangxi Zhuang Autonomous Region, China.
Ling ShenDepartment of Oncology, The First People's Hospital of Nanning, Nanning 530022, Guangxi Zhuang Autonomous Region, China.
Lu ZhouDepartment of Oncology, The First People's Hospital of Nanning, Nanning 530022, Guangxi Zhuang Autonomous Region, China.
Jian-Xun LuDepartment of Oncology, The First People's Hospital of Nanning, Nanning 530022, Guangxi Zhuang Autonomous Region, China. lujianxun1970@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough tumors of the lacrimal sac are rare, they represent a potentially life-threatening situation that can easily be overlooked since patients present with features consistent with chronic dacryocystitis. Lacrimal sac squamous cell carcinoma is the most common lacrimal sac malignancy, but no definitive treatment is currently available. CASE SUMMARY: We describe a 34-year-old unmarried male who presented with a red and swollen right lower eyelid, which gradually developed into a mass of the lower eyelid that obstructed vision in his right eye. He was treated with transcatheter arterial infusion chemotherapy and interventional embolization based on the tumor characteristics, and we also administered intensity-modulated radiotherapy and targeted therapy after tumor shrinkage. The tumor treatment demonstrated good efficacy, and the patient's condition was stable after 10 mo of follow-up.

conclusionTo our knowledge, this is the first report of lacrimal sac squamous cell carcinoma treated with transcatheter arterial infusion chemotherapy and interventional embolization, which might expand clinical treatment options for lacrimal sac carcinoma.

Indexed as

Case reportLacrimal sac squamous cell carcinomaTranscatheter arterial infusion chemotherapy

Identifiers

PMID36157994
PMCPMC9353896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.